Want to see ES:ORY full AI Analyst Report?
Top Page
Oryzon Genomics SA
(BME:ORY)
Select Model
Select Model
Rating:47Neutral
Price Target:
€3.00
▲(0.33% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily weighed down by weak financial performance—ongoing losses, volatile/zero revenue years, and sustained negative free cash flow—partly offset by a comparatively supportive balance sheet with modest leverage. Technical indicators are broadly neutral and do not provide a strong positive catalyst, while valuation metrics are constrained by loss-making status (negative P/E) and no dividend yield.
Positive Factors
Niche epigenetics focus
Oryzon's focused expertise in epigenetics creates a durable competitive niche with high scientific barriers to entry. Specialized small-molecule programs in oncology and CNS increase the chance of differentiated assets, making the company an attractive partner for licensing and late-stage collaborators over multi-year development cycles.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means the company cannot self-fund development and must rely on financing or partner deals. Over 2–6 months this structural cash burn pressures capital management, raises dilution risk, and constrains ability to escalate multiple clinical programs simultaneously without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche epigenetics focus
Oryzon's focused expertise in epigenetics creates a durable competitive niche with high scientific barriers to entry. Specialized small-molecule programs in oncology and CNS increase the chance of differentiated assets, making the company an attractive partner for licensing and late-stage collaborators over multi-year development cycles.
Read all positive factors
Oryzon Genomics SA (ORY) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€236.04M
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue GrowthN/A
EPS Growth53.50%
CountryES
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.28Price Target Upside177.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.1
Revenue Forecast (FY)€6.56M
Oryzon Genomics SA Business Overview & Revenue Model
Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinica...
How the Company Makes Money
Oryzon Genomics primarily makes money through (1) collaboration and licensing arrangements and (2) other income typical of a clinical-stage biotech while it advances its pipeline. In a licensing/collaboration model, Oryzon may grant partners right...
Oryzon Genomics SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.22M | 0.00 | 7.36M | 14.19M | 0.00 | 10.62M |
| Gross Profit | 3.98M | -133.91K | 7.06M | 13.95M | 15.23M | 9.87M |
| EBITDA | -6.56M | -6.29M | -4.43M | -4.43M | -5.35M | -6.88M |
| Net Income | -2.18M | -2.61M | -3.67M | -3.35M | -4.23M | -4.69M |
Balance Sheet | ||||||
| Total Assets | 141.70M | 144.52M | 108.72M | 106.90M | 103.70M | 95.38M |
| Cash, Cash Equivalents and Short-Term Investments | 22.12M | 28.37M | 5.62M | 12.26M | 21.32M | 28.72M |
| Total Debt | 7.10M | 11.94M | 16.21M | 13.69M | 17.44M | 17.66M |
| Total Liabilities | 23.41M | 26.68M | 21.67M | 25.13M | 31.13M | 24.12M |
| Stockholders Equity | 104.32M | 105.45M | 87.04M | 81.77M | 72.57M | 71.26M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.42M | -13.40M | -15.08M | -16.12M | -15.39M |
| Operating Cash Flow | 0.00 | -2.36M | -5.69M | -574.96K | -1.85M | -3.63M |
| Investing Cash Flow | 0.00 | -11.04M | -7.81M | -14.50M | -14.27M | -11.72M |
| Financing Cash Flow | 0.00 | 36.13M | 6.87M | 6.02M | 8.71M | 4.12M |
Oryzon Genomics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €1.40B | 24.23 | 23.64% | 1.25% | 15.52% | 34.76% | |
58 Neutral | €1.42B | 13.74 | 18.19% | 4.89% | 31.88% | -20.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €219.01M | 49.26 | 2.01% | 0.74% | -3.23% | -60.06% | |
47 Neutral | €236.04M | -92.31 | -2.03% | ― | ― | 53.50% |
* Healthcare Sector Average
ES:ORY
Oryzon Genomics SA
2.91
0.29
11.28%
ES:FAE
Faes Farma
4.52
0.39
9.50%
ES:RJF
LABORATORIO REIG JOFRE
2.71
-0.23
-7.70%
ES:PHM
Pharma Mar SA
78.40
1.54
2.00%
ES:IKM
1nKemia IUCT Group SA
0.31
0.00
0.00%
Oryzon Genomics SA Corporate Events
Oryzon Genomics Restates 2025 Interim Results After Accounting Policy Change
Jul 28, 2026
Oryzon Genomics has updated its accounting treatment for capitalization of financial expenses related to development intangibles financed by public loans at zero or below-market interest rates, leading to a restatement of its interim figures for t...
Oryzon Genomics Updates Loyalty Share Voting Rights Structure
Jul 22, 2026
Oryzon Genomics SA has reported the deregistration of 2,390,000 shares that previously carried double voting rights under its loyalty share scheme, reducing the pool of enhanced voting shares. Following this adjustment, the company now has 6,474,4...
Oryzon Genomics Completes €12 Million Share Capital Increase
Jul 7, 2026
Oryzon Genomics SA has completed and fully paid up a share capital increase amounting to €12,000,001.50, with the deed of the capital increase executed and registered in the Commercial Registry of Madrid on July 2, 2026. Following this trans...
Oryzon Genomics Raises €12 Million Through Discounted Private Share Placement
Jul 2, 2026
Oryzon Genomics has completed an accelerated private placement, raising approximately €12 million through a capital increase by issuing 4,444,445 new shares at €2.70 per share, a discount to recent market prices. The new shares, repres...
Oryzon Genomics Shareholders Approve All Resolutions at 2026 General Meeting
Jul 2, 2026
Oryzon Genomics SA announced that all resolutions presented at its ordinary general shareholders’ meeting held on June 26, 2026, were approved by the required majority, indicating broad investor support for the company’s governance and...
Oryzon Genomics launches capital raise and secures €25m anchor commitment for R&D
Jul 1, 2026
Oryzon Genomics has approved a cash capital increase of up to €10 million, potentially rising to €15 million, via an accelerated private placement of new shares aimed at strengthening its balance sheet and speeding up its acute myeloid...
Oryzon Updates Loyalty Share Double Voting Rights and Total Votes
Jun 9, 2026
Oryzon Genomics has updated its share capital structure after the removal of 102,530 shares that carried double voting rights for shareholder loyalty. Following this adjustment, the company now reports 8,864,432 shares with double voting rights an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.